MarketResearchReports.Biz Syndicated research Report And Forecast On "Bladder Cancer - Opportunity Analysis And Forecasts To 2017"
MarketResearchReports.Biz present overview on "Bladder Cancer - Opportunity Analysis And Forecasts To 2017"
The bladder cancer market has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition, bladder cancer has a robust early-stage pipeline that will contribute to market growth beyond the forecast period of 2012-2017. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy.
Though initially effective, toxicity and lack of clinical efficacy in improving overall survival have left the door open for more tolerable and effective drugs to be developed. In the past, bladder cancer has not been an area of focus for pharmaceutical companies, but that is rapidly changing as more companies focus on the bladder cancer market, recognizing the high level of unmet need and relatively clear regulatory path. During the forecast period, the market landscape will begin to change dramatically with the introduction of targeted immunotherapies. These drugs will provide much-needed alternatives to bladder cancer patients who have not benefitted from traditional treatments.
Download The sample Copy Of This Report @ http://www.marketresearchreports.biz/sample/sample/547962
Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized bladder cancer therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for 5 years to 2017.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the bladder cancer therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Bladder cancer is a urologic malignancy arising from the epithelial lining of the urinary bladder. Although it is the ninth most common cancer worldwide in men and women, with the highest recurrence rate of any malignancy, relatively little is known about its etiology. There has been little development over the past 20 years in bladder cancer, with a huge void of unmet met needs which are yet to be filled. The disease can be spilt into three main categories; NMIBC (non-muscle invasive bladder cancer), muscle invasive disease and metastatic disease.